Surrozen reports Q1 financial results focused on ophthalmology pipeline, discontinuing SZN-043 for alcohol-associated hepatitis.

From GlobeNewswire: 2025-05-09 16:05:00

Surrozen, Inc. announced financial results for Q1 2025, focusing on ophthalmology pipeline for severe eye diseases. They discontinued SZN-043 for alcohol-associated hepatitis due to lack of benefit. Lead candidates SZN-8141 and SZN-8143 show promise, with plans to file IND application in 2026. Collaboration with Boehringer Ingelheim continues for retinal vascular diseases.

Financially, Surrozen’s cash position was $101.6 million as of March 31, 2025, bolstered by a private placement. Research service revenue from a related party was $1.0 million. Operating expenses increased due to R&D costs. Net loss for Q1 2025 was $27.0 million, compared to $8.8 million in Q1 2024.

SZN-8141 for retinal diseases combines Fzd4 agonism with VEGF antagonism, showing potential benefits for DME and wet AMD. SZN-8143 adds IL-6 antagonism for potential benefits in DME, wet AMD, and UME. SZN-413 targets retinal vascular-associated diseases with the potential to stimulate Wnt signaling and reduce vascular leakage for healthy eye tissue regeneration.



Read more at GlobeNewswire:: Surrozen Reports First Quarter 2025 Financial Results and